>   >   >  Framingham研究

1) Dustan HP. History of clinical hypertension: from 1982 to 1970. In: Oparil S, Weber MA, editors. Hypertension: a companion to Brenner and Rector's the kidney. Philadelphia: WS Saunders Company; 2000.p.1-19.

2) Kannel WB. Risk factors in hypertension. J Cardiovasc Pharmacol 1989; 13(Suppl 1): S4-10.

3) Futterman LG, Lemberg L. The Framingham Heart Study: a pivotal legacy of the last millennium. Am J Cit Care 2000; 9: 147-51.

4) Kannel WB. Fifty year of Framingham study contri-butions to understanding hypertension. J Hum Hyper-tens 2000; 14: 83-90.

5) Kannel WB. The Framingham study: its 50-year legacy and future promise. J Atheroscler Thromb 2000; 6: 60-6.

6) D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF, et al. Primary and coronary appraisal:new results from the Framingham Study. Am Heart J 2000; 139: 272-81.

7) Dawber TR, Kannel WB, Revotskie N, Stokes J III, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study. Am J Pub Health 1959; 49: 1349-56.

8) Truett J, Cornfield J, Kannel W. Amultivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967; 20: 511-24.

9) Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8.

10) Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary heart disease: the Framingham Study. Am Heart J 1990; 120: 963-9.

11) Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure:the Framingham Study. Circulation 1997; 96: 308-15.

12) Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive persons: the Framin-gham Study. Am Heart J 1993; 125: 1154-8.

13) Kannel WB. Hypertension and the risk of cardiovascular disease. In: Laragh JH, Brenner BM, editors. Hyperten-sion: pathology, diagnosis, and management. New York: Raven Press; 1990. p.101-7.

14) Tell GS, Rutan GH, Kronmal RA, Bild DE, Polak JF, Wong ND, et al. For the Cardiovascular Health Study (CHS) Collaborative Research Group: correlates of blood pressure in community-dwelling older adults: the Cardiovascular Health Study. Hypertension 1994; 23: 59-67.

15) Franklin SS. Ageing and hypertension: the assessment of blood pressure induces in predicting coronary heart disease. J Hypertens 1999; 17(Suppl 5): S29-36.

16) Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993; 329: 1912-7.

17) Franklin SS, Jacobs MJ, Wong ND, L'Iyalien GJ, Lapuerta P. Predominance of isolated systolic hyper-tension among middle-aged and elderly US hypereten-sives: analysis based on National Health and Nutrition Examination Survey(NHANES)III. Hypertension 2001; 37: 869-74.

18) Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-5.

19) Vokonas PS, Kannel WB, Cupples LA. Epidemiology and riak of hypertension: the Framingham Study. J Hyper-tens 1988; 6(Suppl 1): S3-9.

20) Kannel WB. Histolic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138(3 part 2): S205-10.

21) Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham Study. Circula-tion 1980; 61: 1179-82.

22) Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging?: the Framingham Heart Study. Circulation 2001; 103: 1245-9.

23) Franklin SS, Kahn SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease?: the Framingham Heart Study. Circula-tion 1999; 100: 354-60.

24) Benetos A, Thomas F, Safar ME, Bean KE, Guize L. Should diastolic and systolic blood pressure considered for cardiovascular risk evaluation: a study in middle-aged men and women. J Am Coll Cardiol 2001; 37: 163-8.

25) Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.

26) Kannel WB, D'Agostino PB, Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J 1997; 134: 758-63.

27) Boshuizen HC, Izaks GJ, van Buuren S, Ligthart GJ. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ 1998; 316: 1780-4.

28) Shea S, Cook EF, Kannel WB, Goldman L. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study. Circu-lation 1985: 71: 22-30.

29) Mosterd A, D'Agostino PB, Silbershatz H, Sytkowski PA, Kannel WB, Grobee DE, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221-7.

30) Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hyperten-sion, long-term treatment, and cardiovascular morta-lity: the Framingham Heart Study 1950-1990. Circula-tion 1996; 93: 697-703.

31) D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study. Stroke 1994; 25: 40-3.

32) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.

33) Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-9.

34) Abascal VM, Larson MG, Evans JC, Blohm AT, Poli K, Levy D. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study. Arch Intern Med 1998; 158: 1882-6.

35) Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-54.

36) Thomas F, Bean K, Provost JC, Guize L, Benetos A. Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age. J Hypertens 2001; 19: 863-9.

37) Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham Heart Study. Circulation 1994; 90: 878-83.

38) Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309-12.

39) Kannel WB. Hypertension: relationship with other risk factors. Drugs 1986; 31(Suppl 1): S1-11.

40) Levy D, Gsrrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.

41) Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-84.

42) Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccino C, et al. Adverse prognostic significance of concentric remodeling of the left ventri-cle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-8.

43) Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA 1994; 272: 33-6.

44) Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electro-cardiographic features and their serial changes in sub-jects with left ventricular hypertrophy. Circulation 1994; 90: 1786-93.

45) Benjamin EJ, Levy D. Why is left ventricular hyper-trophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317: 168-75.

46) Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry the Framingham Heart Study. JAMA 1991; 266: 231-6.

47) Manolio TA, Levy D, Garrison RJ, Castelli WP, Kannel WB. Relation of alcohol intake to left ventricular mass: the Framingham Study. J Am Coll Cardiol 1991; 17: 717-21.

48) Stokes JV, Kannel WB, Wolf PA, Cupples LA, D'Agostino PB. The relative importance of selected risk factors for various manifestations of cardiovascular dis-ease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987; 75(Suppl V): S65-73.

49) Strasser T. Equal blood pressure levels carry different risk in different risk factor combinations. J Hum Hyper-tens 1992; 6: 261-4.

50) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62: 707-14.

51) Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1988; 4(Suppl A): S5-10.

52) Lipid Research Clinics Program: the Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.

53) Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PWF, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framin-gham Heart Study. Clin Chem 1999; 45: 1039-46.

54) Gordon T, Castelli WP, Hojortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women:the Framingham study. Ann Intern Med 1977; 87: 393-7.

55) Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteina, apolipoproteins, and low-density lipopro-tein size among doabetics in the Framingham offspring study. Metabolism 1996; 45: 1267-72.

56) Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.

57) Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysyeine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.

58) Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysyeine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131: 352-5.

59) Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham study. Am J Epidemiol 1989; 130: 469-80.

60) D'Agostino PB, Belanger A, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart death in the presence of myocardial infarction: the Framingham study. BMJ 1991; 303: 385-9.

61) Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Med 1994; 74: 236-41.

62) Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(Suppl 8A): S2-9.

63) Yusuf S, Throm T, Abbott RD. Changes in hypertension treatment and in congestive heart failure in United States. Hypertension 1989; 13(Suppl I): S74-9.

64) Levy D, Larson MG, Vasan RS, Kannel WB, Ho KLL. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.

65) Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med 1996; 156: 1789-96.

66) Kannel WB. Framingham study insights into hyperten-sive risk of cardiovascular disease. Hypertens Res 1996; 18: 181-96.

67) Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106: 606-12.

68) Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997; 336: 1350-5.

69) Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D.Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population based cohort. J Am Coll Cardiol 1999; 33: 1948-55.

70) Lloyd-Jones DM. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr Cardiol Reprts 2001; 3: 184-90.

71) Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. Arch Intern Med 1996; 156: 505-9.

72) Visser M, Harris TB, Langlois J, Hannan MT, Roubenoff R, Felson DT, et al. Body fat and skeletal muscle mass in relation to physical disability in very old men and women of the Framingham Heart Study. J Gerontol A Biol Sci Med Sci 1998; 53: M214-21.

73) Gordon T, Kannel WB. Drinking and its relation to smoking, BP, blood lipids, and uric acid: the Framing-ham study. Arch Intern Med 1983; 143: 1366-74.

74) Elias PK, Elias MF, D'Agostino RB, Silbershatz H, Wolf PA. Alcohol consumption and cognitive performance in the Framingham Heart Study. Am J Epidemiol 1999; 150: 580-9.

75) Djousse L, Levy D, Murabito JM, Cupples LA, Ellison RC. Alcohol consumption and risk of intermittent claudication in the Framingham Heart Study. Circulation 2000; 102: 3092-7.

76) Felson DT, Zhang Y, Hannan MT, Kannel WB, Kiel DP. Alcohol intake and bone mineral density in elderly men and women: the Framingham Study. Am J Epidemiol 1995; 42: 485-92.

77) Gordon T, Kannel WB. Drinking and mortality: the Framingham Study. Am J Epidemiol 1984; 120: 97-107.

78) WHO Expert Committee. Hypertension control. Report of a WHO Expert Committee. World Health Organi-zation Technical Report Series 862; 1996. p.1-83.

79) Guidelines Subcommittee. 1999 World Health Organiza-tion-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.

80) Ramsey LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-92.

81) European Society of Cardiology, European Atherosclero-sis Society, European Society of Hypertension, Interna-tional Society of Behavoural Medicine, European Socie-ty of General Practice/Family Medicine, European Heart Network. Prevention of coronary heart diseasein clinical Practice: recommendations of the Second Joint Task Force of European and other Societies of Coronary Prevention. Eur Heart J 1998; 19: 1434-503.

82)Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a steatement for healthcare pro-fessionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163-82.

83)D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study. Stroke 1994; 25: 40-3.

84)Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hyper-tensive patients according o the JNC VI risk stratifi-cation. Hypertension 2000; 35: 539-43.

85)Lloyd-Jones DM, Evans JC, Larson MG, O'Donell CJ, Wilson PW, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framing-ham Heart Study. Arch Intern Med 1999; 159: 2206-12.